Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - Protocol of a randomized phase II trial (NOA 10/ARO 2013-1)

Oliver Oehlke, Michael Mix, Erika Graf, Tanja Schimek-Jasch, Ursula Nestle, Irina Götz, Sabine Schneider-Fuchs, Astrid Weyerbrock, Irina Mader, Brigitta Baumert, Susan C. Short, Philipp T. Meyer, Wolfgang A. Weber, Anca-Ligia Grosu

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The higher specificity of amino-acid positron emission tomography (AA-PET) in the diagnosis of gliomas, as well as in the differentiation between recurrence and treatment-related alterations, in comparison to contrast enhancement in T1-weighted MRI was demonstrated in many studies and is the rationale for their implementation into radiation oncology treatment planning. Several clinical trials have demonstrated the significant differences between AA-PET and standard MRI concerning the definition of the gross tumor volume (GTV). A small single-center non-randomized prospective study in patients with recurrent high grade gliomas treated with stereotactic fractionated radiotherapy (SFRT) showed a significant improvement in survival when AA-PET was integrated in target volume delineation, in comparison to patients treated based on CT/MRI alone.

Methods: This protocol describes a prospective, open label, randomized, multi-center phase II trial designed to test if radiotherapy target volume delineation based on FET-PET leads to improvement in progression free survival (PFS) in patients with recurrent glioblastoma (GBM) treated with re-irradiation, compared to target volume delineation based on T1Gd-MRI. The target sample size is 200 randomized patients with a 1: 1 allocation ratio to both arms. The primary endpoint (PFS) is determined by serial MRI scans, supplemented by AA-PET-scans and/or biopsy/surgery if suspicious of progression. Secondary endpoints include overall survival (OS), locally controlled survival (time to local progression or death), volumetric assessment of GTV delineated by either method, topography of progression in relation to MRIor PET-derived target volumes, rate of long term survivors (>1 year), localization of necrosis after re-irradiation, quality of life (QoL) assessed by the EORTC QLQ-C15 PAL questionnaire, evaluation of safety of FET-application in AA-PET imaging and toxicity of re-irradiation.

Discussion: This is a protocol of a randomized phase II trial designed to test a new strategy of radiotherapy target volume delineation for improving the outcome of patients with recurrent GBM. Moreover, the trial will help to develop a standardized methodology for the integration of AA-PET and other imaging biomarkers in radiation treatment planning.

Original languageEnglish
Article number769
Number of pages10
JournalBMC Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 5 Oct 2016

Keywords

  • Amino-acid PET
  • T1-Gd-MRI
  • Re-irradiation
  • Recurrent glioblastoma

Cite this

Oehlke, O., Mix, M., Graf, E., Schimek-Jasch, T., Nestle, U., Götz, I., Schneider-Fuchs, S., Weyerbrock, A., Mader, I., Baumert, B., Short, S. C., Meyer, P. T., Weber, W. A., & Grosu, A-L. (2016). Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - Protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 16(1), [769]. https://doi.org/10.1186/s12885-016-2806-z